TrialJournal of the National Comprehensive Cancer Network : JNCCN2012

A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.

Matthew G Fury et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.